Editorial overview: Anti-infectives: Towards novel antiviral and antibacterial drugs? Current approaches to address a growing medical need

Current Opinion in Pharmacology

Volumn 18, Issue , 2014, Pages iv-vi

  Docquier, Jean Denis ^a   Cusi, Maria Grazia ^a,b  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; COLISTIN; MARAVIROC; PENICILLIN BINDING PROTEIN; PENICILLIN DERIVATIVE; PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIVIRAL RESISTANCE; BACTERIUM ISOLATE; BIOFILM; DRUG COST; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG RESEARCH; DRUG RESISTANCE; DRUG TARGETING; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEALTH CARE NEED; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOCOMPROMISED PATIENT; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PANDRUG RESISTANCE; PHENOTYPE; REVIEW; VIRUS ISOLATION; VIRUS REPLICATION; HEPATITIS C; HIV INFECTIONS;

ANTI-BACTERIAL AGENTS; ANTIVIRAL AGENTS; DRUG RESISTANCE, BACTERIAL; HEPATITIS C; HIV INFECTIONS; HUMANS;

EID: 84909619629     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2014.10.004     Document Type: Editorial

References (11)

1. N. Kardos, and A.L. Demain Penicillin: the medicine with the greatest impact on therapeutic outcomes Appl Microbiol Biotechnol 92 2011 677 687
2. K. Lewis Platforms for antibiotic discovery Nat Rev Drug Discov 12 2013 371 387
3. D.M. Livermore Has the era of untreatable infections arrived? J Antimicrob Chemother 64 Suppl. 1 2009 i29 i36
4. P. Nordmann, L. Poirel, M.A. Toleman, and T.R. Walsh Does broad-spectrum beta-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? J Antimicrob Chemother 66 2011 689 692
5. M. McKenna Antibiotic resistance: the last resort Nature 499 2013 394 396
6. World Health Organization Antimicrobial resistance: global report on surveillance 2014 978 92 4 156474 8 http://www.who.int/drugresistance/documents/surveillancereport/en/
7. S.J. Projan Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 6 2003 427 430
8. U. Theuretzbacher Accelerating resistance, inadequate antibacterial drug pipelines and international responses Int J Antimicrob Agents 39 2012 295 299
9. N. Srinivas, P. Jetter, B.J. Ueberbacher, M. Werneburg, K. Zerbe, J. Steinmann, B. Van der Meijden, F. Bernardini, A. Lederer, R.L. Dias, P.E. Misson, H. Henze, J. Zumbrunn, F.O. Gombert, D. Obrecht, P. Hunziker, S. Schauer, U. Ziegler, A. Käch, L. Eberl, K. Riedel, S.J. DeMarco, and J.A. Robinson Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa Science 327 2010 1010 1013
10. K.S. Reynolds Combining forces to combat infectious diseases Clin Parmacol Ther 96 2014 123 126
11. Z. Lou, Y. Sun, and Z. Rao Current progress in antiviral strategies Trends Pharmacol Sci 35 2014 86 102